1. On Monday, Endo Int’l (Nasdaq: ENDP) and Par Pharmaceutical Holdings, Inc., announced that they have entered into a definitive agreement under which Endo will acquire privately-held Par from TPG in a transaction valued at $8.05 billion, including assumption of Par debt. The purchase price will consist of approximately 18 million shares ($1.55 billion of value based on the 10-day volume weighted average share price of Endo ending on May 15, 2015) of Endo equity and $6.50 billion cash consideration to Par shareholders.
2. Apple shares got a boost on Monday after Carl Icahn issued a